Cargando…

Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms

Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a basel...

Descripción completa

Detalles Bibliográficos
Autor principal: Thanvi, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271003/
https://www.ncbi.nlm.nih.gov/pubmed/35818415
http://dx.doi.org/10.1155/2022/3684181
_version_ 1784744585016115200
author Thanvi, Vikas
author_facet Thanvi, Vikas
author_sort Thanvi, Vikas
collection PubMed
description Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD.
format Online
Article
Text
id pubmed-9271003
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92710032022-07-10 Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms Thanvi, Vikas Case Rep Psychiatry Case Report Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD. Hindawi 2022-07-02 /pmc/articles/PMC9271003/ /pubmed/35818415 http://dx.doi.org/10.1155/2022/3684181 Text en Copyright © 2022 Vikas Thanvi. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Thanvi, Vikas
Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title_full Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title_fullStr Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title_full_unstemmed Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title_short Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
title_sort real-world long-term experience on endoxifen in bipolar disorder with psychotic symptoms
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271003/
https://www.ncbi.nlm.nih.gov/pubmed/35818415
http://dx.doi.org/10.1155/2022/3684181
work_keys_str_mv AT thanvivikas realworldlongtermexperienceonendoxifeninbipolardisorderwithpsychoticsymptoms